Home > Insider Trading > Filing (0000874015-21-000136)

Filing Details

Accession Number:: 0000874015-21-000136
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-19 20:14:14
Reporting Period:: 2021-07-15

Accepted Time:: 2021-07-19 20:14:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Ionis Pharmaceuticals Inc	IONS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1206369	Iii Joseph Klein	2855 Gazelle Court Carlsbad CA 92010		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-07-15	5,333	$0.00	19,127	No	4	M	Direct
Common Stock	Acquisiton	2021-07-15	889	$0.00	20,016	No	4	M	Direct
Common Stock	Acquisiton	2021-07-15	666	$0.00	20,682	No	4	M	Direct
Common Stock	Acquisiton	2021-07-15	1,778	$0.00	22,460	No	4	M	Direct
Common Stock	Disposition	2021-07-15	4,334	$35.30	18,126	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2021-07-15	5,333	$0.00	5,333	$0.00
Common Stock	Restricted Stock Unit	Disposition	2021-07-15	889	$0.00	889	$0.00
Common Stock	Restricted Stock Unit	Disposition	2021-07-15	666	$0.00	666	$0.00
Common Stock	Restricted Stock Unit	Disposition	2021-07-15	1,778	$0.00	1,778	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,108	No	4	M	Direct
12,219	No	4	M	Direct
11,553	No	4	M	Direct
9,775	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	100	Indirect	by Son

Footnotes

Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.78 to $35.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.
Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.